New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
19:09 EDTVRNT, MDR, CBST, AMRN, DRTX, ARTX, MDCOOn The Fly: After Hours Movers
HIGHER: Durata Therapeutics (DRTX), up 5.4% after an FDA Committee voted in favor of its Dalvance injection for the treatment of adult patients with acute bacterial skin and skin structure infections caused by certain bacteria... Amarin (AMRN), up 8.8% after announcing a co-promotion agreement with Kowa Pharmaceuticals America for its Vascepa capsules in the U.S... Verint Systems (VRNT), up 10% after reporting earnings that beat expectations and providing a fiscal year outlook that also topped estimates. LOWER: The Medicines Company (MDCO), down 14.3% after Durata and Cubist Pharmaceuticals (CBST) each received positive votes from FDA panels for bacteria treatments that could compete with its Oritavancin. Cubist (CBST), which confirmed the FDA panel vote intraday, saw shares gain $3.05, or 4.35%, to close at $73.15 for the session... Arotech (ARTX), down 12.5% after reporting fiscal year earnings and revenue that disappointed... McDermott (MDR), down 2.8% after filing to sell 10M tangible equity units and, in a separate release, saying that its first quarter results may differ "substantially" from the company's current expectation.
News For DRTX;MDR;MDCO;AMRN;VRNT;ARTX;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
09:23 EDTAMRNAmarin, Eddingpharm agree to develop, commercialize Vascepa in China
Amarin Corporation and Eddingpharm announced an exclusive agreement for Eddingpharm to develop and commercialize Vascepa in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan for uses that are currently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa. Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169M, including a non-refundable $15M up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154M. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.
09:00 EDTAMRNAmarin trading halted, pending news
Subscribe for More Information
February 25, 2015
05:20 EDTMDRMcDermott and Petrofac form five-year strategic alliance
McDermott and Petrofac Limited announced they have formed a strategic marketing alliance to pursue top-tier deepwater subsea, umbilical, riser and flowline, or SURF, projects. The five-year alliance expects to provide oil and gas companies a competitive, integrated solution across a broad range of complex engineer, procure, construct, install Subsea projects in deep and ultra-deepwater across the US Gulf of Mexico, Mexico, Brazil, the North Sea, Mediterranean and West Africa. SURF projects are expected to be above $200M, with the project scope anticipated to be split between partners roughly equally, but according to the specifics of a particular opportunity, and governed by separate project agreements.
February 20, 2015
16:03 EDTAMRNOptions Update; February 20, 2015
Subscribe for More Information
10:20 EDTAMRNHigh option volume stocks
Subscribe for More Information
09:38 EDTAMRNActive equity options trading on open
Subscribe for More Information
February 18, 2015
10:05 EDTAMRNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
09:10 EDTAMRNOn The Fly: Pre-market Movers
Subscribe for More Information
08:54 EDTMDCOThe Medicines Co. anticipates potential partnership talks
Subscribe for More Information
08:52 EDTMDCOThe Medicines Co. anticipates four U.S. FDA approvals in 2015
08:41 EDTMDCOThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
07:01 EDTMDCOThe Medicines Co. reports Q4 adjusted EPS 20c, consensus (82c)
Subscribe for More Information
06:05 EDTAMRNAmarin upgraded to Buy from Neutral at SunTrust
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use